RALEIGH, N.C., July 31, 2013 /PRNewswire/ -- Researchers from LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, are presenting two posters today that highlight the utility of the company's proprietary nuclear magnetic resonance (NMR) technology in measuring novel markers of systemic inflammation, as well as in diagnosing diabetes through measurement of blood glucose. The posters, which will be presented during the Technology/Design Development session at the American Association of Clinical Chemistry (AACC) annual meeting in Houston, Tex., will be on display today from 9:30 a.m. to 5:00 p.m.
GlycA and GlycB: Novel Markers of Systemic Inflammation
In one poster (#B-255), James Otvos and colleagues at LipoScience will present data on two novel markers of systemic inflammation, GlycA and GlycB that were derived from stored serum NMR spectra. Data collected at baseline from 5,680 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) showed that GlycA and GlycB levels were associated with C-reactive protein (CRP, r~0.5-0.6) and fibrinogen, two acute-phase proteins that are commonly used to assess and monitor both acute and chronic inflammation. GlycA was also associated, independent of traditional risk factors, with future (6-year follow-up) coronary heart disease (CHD) events as well as with diabetes, all-cause death, and cancer.
"These data suggest that measurement of GlycA and GlycB via NMR spectroscopy can provide an assessment of inflammation status that is similar or complementary to existing inflammatory biomarkers, thereby aiding in risk assessment for inflammation-mediated cardiovascular disease," stated Dr. Otvos, who is Chief Scientific Officer at LipoScience. "Moreover, these novel markers of inflammation can be detected from NMR LipoProfile test spectra, which can further illuminate a patient's cardiovascular disease risk profile through quantification of lipoprotein particles in a blood sample."High-Throughput Measurement of Serum Glucose in the Clinical Laboratory by NMR In the second poster (#B-245), Dr. Thomas O'Connell and colleagues will demonstrate how a blood glucose assay, developed using NMR technology for LipoScience's Vantera ® Clinical Analyzer, can enable high-throughput measurement of glucose to aid in the diagnosis of diabetes and pre-diabetes. When comparing glucose measurements made by NMR to those made by a standard chemistry assay, the investigators reported an excellent correlation between methods. "While the fully automated Vantera Clinical Analyzer is currently used for measurement of lipoprotein particle concentrations, the information-rich nature of the NMR spectrum enables other clinically valuable metabolites such as glucose to be measured in the same spectrum," explained Dr. O'Connell. "Our results highlight the suitability of NMR for high-throughput automated quantification of glucose, which may facilitate diagnosis of diabetes and pre-diabetes."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts